ALNAOCAS

PreclinicalSmall molecule

Boehringer Ingelheim

ALNAOCAS is one of 31 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

Benign Prostatic HyperplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

110 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

1 2

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

2 3

Tamsulosin OCAS

Astellas

Phase 3

5 4

Botox

AbbVie

Phase 3

2 5

Evista

Eli Lilly

Phase 2

1 6

Drug Therapy

MMassachusetts General Hospital

Phase 3

1 7

Botox

RRevance Therapeutics, Inc.

Phase 2

3 8

Firmagon

Ferring

Phase 2

2 9

Viagra

VViatris Specialty LLC

Phase 2

1 10

Zesly

MMezzion Pharma Co. Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02245542·5,775 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALNAOCAS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALNAOCAS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALNAOCAS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

ALNAOCAS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News